Literature DB >> 29414834

Phosphate Removal During Conventional Hemodialysis: a Decades-Old Misconception.

Rosilene M Elias1, Valeria R C Alvares1, Rosa M A Moysés1,2.   

Abstract

BACKGROUND/AIMS: Hyperphosphatemia is associated with high mortality rate in patients on dialysis. Conventional hemodialysis (HD) is a limit technique in removing phosphate (P). There is a widespread belief that P is removed mainly in the first hour of HD. The aim of this study was to certify the percentage of 1-hour removal of P as compared to the entire procedure.
METHODS: data from the first dialysis of the week of 21 patients (13 men, age 44±15 years), for 3 consecutive dialysis sessions were evaluated. Fresh dialysate samples were collected at 1 hour and at the end of the session from a partial spent dialysate collection method.
RESULTS: Pre dialysis serum P was 4.7±1.7 mg/dl. Reduction rate of serum P was 47.4 ± 14.3 and 45.1 ± 10.8% in 1- and 4-hour of HD, respectively (p=0.322). P removal was 194 (145, 242) mg in 1-hour (p<0.0001), which represents 25.0 ± 0.2% of the total removed during the entire HD. Patients with pre dialysis P ≥ 5.5mg/dl had higher P removal during HD than those with P < 5.5mg/dl [975 (587, 1354) vs. 776 (580, 784) mg, p=0.025], although the percentage of removal in 1 hour was not different from those with P < 5.5mg/d (24.9 ± 0.3 vs. 25.0 ± 0.1%, p=0.918). P removal during dialysis correlated with pre dialysis serum P (r=0.455, p=0.001), parathormone (r=0.264, p=0.037) and ultrafiltration volume (r=0.343, p=0.019).
CONCLUSION: despite the P serum concentration normalizing in the first hour of hemodialysis, the removal in the same period reaches only 25% of the entire session.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Dialysate; Hemodialysis; Hyperphosphatemia; Phosphate removal

Mesh:

Substances:

Year:  2018        PMID: 29414834     DOI: 10.1159/000487108

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  4 in total

Review 1.  Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.

Authors:  Ezequiel Bellorin-Font; George Vasquez-Rios; Kevin J Martin
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

2.  EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.

Authors:  Kathleen M Hill Gallant; Elizabeth R Stremke; Laurie L Trevino; Ranjani N Moorthi; Simit Doshi; Meryl E Wastney; Nozomi Hisada; Jotaro Sato; Yoshitaka Ogita; Naohisa Fujii; Yuya Matsuda; Takei Kake; Sharon M Moe
Journal:  Kidney Int       Date:  2020-10-31       Impact factor: 10.612

Review 3.  The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.

Authors:  Jiameng Li; Liya Wang; Mei Han; Yuqin Xiong; Ruoxi Liao; Yupei Li; Si Sun; Anil Maharjan; Baihai Su
Journal:  Nutr Diabetes       Date:  2019-04-03       Impact factor: 5.097

4.  Hypophosphatemia after hemodialysis and its association with some clinical complications in patients with chronic kidney disease.

Authors:  Mohammadreza Ardalan; Ali Safaei; Audrey Tolouian; Ramin Tolouian; Vahideh Ebrahimzadeh Attari; Mahsa Jalili
Journal:  Caspian J Intern Med       Date:  2022
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.